SAN DIEGO--(BUSINESS WIRE)--Akesis Pharmaceuticals, Inc. (OTCBB:AKES), an emerging diabetes drug-development company, today announced it has appointed Carl LeBel, Ph.D., to serve on its board of directors. Dr. LeBel has more than 17 years of experience as a biopharmaceutical industry executive, including 14 years at Amgen Inc. where he was an executive director for program management and strategic operations. Most recently his responsibilities at Amgen included overseeing global cross-functional program activities for a late-stage development candidate in osteoporosis, and he also has extensive experience in the area of metabolic diseases.
